Vasopressin Biology in Autism: From Biomarker to Treatment Target
Karen J. Parker, PhD, describes scientific barriers to progress in developing laboratory-based diagnostic tests and new medications for patients with autism. She considers the relative scientific merits of published findings from animal models of autism spectrum disorder by assessing their face and construct validity to the human disorder. Parker provides detailed scientific information on the biology of social deficits with an emphasis on vasopressin and oxytocin signaling pathways and biologically informed treatment trials in patients with autism.
Watch Next
SPARKing New Insight into Autism
Wendy Chung M.D., PH.D.
Wendy Chung is the principle investigator of SPARK (Simons Foundation Powering Autism Research for Knowledge), a research study including over…
Heat and fire: Associations of prenatal wildfire smoke and heat exposures on autism development
David Luglio, PhD
Dr. Luglio presents on his two recent environmental epidemiological studies investigating the associations of wildfire smoke and heat exposure during…
Q&A: Brain Imaging Research in Autism
Marvin Natowicz, MD, PhD, Rajesh Kana, PhD
The accredited educational series jointly provided by Autism Research Institute and Cleveland Clinic Center for Continuing Education reviews the co-occurrence…
Brain Imaging Research in Autism: Promises and Pitfalls
Marvin Natowicz, MD, PhD, Rajesh Kana, PhD
The accredited educational series jointly provided by Autism Research Institute and Cleveland Clinic Center for Continuing Education reviews the co-occurrence…